Free Trial
NASDAQ:NAMS

NewAmsterdam Pharma Q1 2025 Earnings Report

NewAmsterdam Pharma logo
$17.96 -0.24 (-1.32%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$18.15 +0.19 (+1.06%)
As of 06/20/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

NewAmsterdam Pharma Revenue Results

Actual Revenue
$2.98 million
Expected Revenue
$1.46 million
Beat/Miss
Beat by +$1.52 million
YoY Revenue Growth
N/A

NewAmsterdam Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

NewAmsterdam Pharma's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

NewAmsterdam Pharma Earnings Headlines

Why Is President Trump Fast-Tracking These Companies?
Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits.
See More NewAmsterdam Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ:NAMS), a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

View NewAmsterdam Pharma Profile

More Earnings Resources from MarketBeat